40144
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Feb 7, 2018
Mexico
Latin America and the Caribbean
Mar 12, 2018
B - Limited
Active
Jul 7, 2018
Regional Industry - MAS LAC
Health, Education and Life Sciences
Approved : Apr 25, 2018
Signed : May 20, 2018
Invested : Jul 2, 2018
Pharmaceuticals and Medicine
Founded in 1996, Genomma Lab Internacional S.A.B. de C.V. ("Genomma" or the “Company”) is a Mexico-based, pharmaceutical company listed in the Mexican Stock Exchange with a presence in 18 countries across Latin America, and in the U.S.. It is focused on the marketing, distribution and sales of over-the-counter (“OTC”) or non-prescription medicines and personal care products. Genomma uses third-party contract manufacturers to manufacture its products, 90 percent of which are manufactured in Mexico).
The purpose of IFC’s proposed financing is to support Genomma’s approximately US$232 million expansion plan over the next 2 years which includes the construction of Genomma’s first manufacturing facility in the state of Mexico, debt refinancing, and other capital expenditures (the “Project”).
IFC is in early discussions with the Company to potentially advise Genomma in the implementation of green building elements to achieve the Excellence in Design for Greater Efficiencies (EDGE) certification, which would be the first pharmaceutical manufacturing plant certified under EDGE worldwide.
For Inquiries About the Project, Contact
For Inquiries and Comments About IFC, Contact
Local Access of Project Documentation
Mr. Antonio Zamora Galland
Chief Financial Officer
Antonio Dovalí Jaime No. 70, Torre C, Piso 2, despacho A Corporativo Samara, Col. Santa Fe, C.P. 01210. Del. Alvaro Obregón, México, D.F.
Telephone: +52 (55) 5081 0000
Email: antonio.zamora@genommalab.com
www.genommalab.com